Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Imarc Group
www.imarcgroup.com/
Kanika Sharma
sales@imarcgroup.com
8130434268
GB Nagar
Nehru Complex

Bookmark and Share
Premenstrual Syndrome Treatment Market 2021-26: Industry Growth, Share, Trends, Demand & Forecast
The Premenstrual Syndrome Treatment Market to grow at a CAGR of XX% during 2021-2026.

BriefingWire.com, 10/13/2021 - According to the latest report by IMARC Group, titled “Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the Premenstrual Syndrome Treatment Market to grow at a CAGR of XX% during 2021-2026.

Premenstrual syndrome (PMS) refers to a set of emotional, physical, and psychological symptoms that occur in women during the end of the luteal phase. It is caused by the elevated levels of progesterone and estrogen. Some of the common PMS symptoms include mood swings, breast tenderness, bloating, fatigue, anxiety, and body pain. PMS treatment involves various medications that help to increase the levels of serotonin hormone in the body. These treatments include analgesics, antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), ovarian suppression agents, and hormonal contraceptives.

Premenstrual Syndrome Treatment Market Trends:

The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) is primarily driving the market growth. The rising awareness regarding the availability of alternative PMS treatment methods is further catalyzing the market growth. In line with this, pharmaceutical companies are investing in research and development (R&D) activities to launch medications with minimal side-effects, which is contributing to the market growth. Additionally, the widespread adoption of plant-based nutritional supplements for PMS relief is presenting numerous growth opportunities to leading players in the market, thus creating a positive outlook for the market.

Request Free Sample Report: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample

Premenstrual Syndrome Treatment Market 2021-2026 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company., GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

The report has segmented the market on the basis on region, disc type, material type and end user.

Breakup by Drug Type:

Analgesics

Antidepressants

Oral Contraceptives and Ovarian Suppression Agents

Others

Breakup by Type:

Prescription

Prescription

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia United

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations.

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2021 Proserve Technology, Inc.